Date,Project_ID,Research_Area,Compound_Name,Molecular_Formula,Concentration_Tested,Method,Results_Summary,Quality_Score,Safety_Rating,Regulatory_Status,Citations,Lead_Researcher,Collaborators,Next_Steps,Budget_Used,Patent_Potential,Commercial_Viability,Notes
2025-01-01,TC-001,Terpene Formulation,D-Limonene,C10H16,25%,GC-MS Analysis,Optimal concentration for mood enhancement,8.5,GRAS,FSA Approved,PMC123456;PMC789012,Dr. Smith,University Lab A,Scale to production,£250,Medium,High,Initial baseline study
2025-01-02,TC-002,Aromatherapy Applications,Beta-Myrcene,C10H16,40%,Sensory Evaluation,Strong relaxation effects observed,9.2,GRAS,Under Review,PMC345678;PMC901234,Dr. Johnson,Clinical Partner B,Consumer testing,£180,Low,High,Consumer preference testing needed
2025-01-03,TC-003,Delivery Methods,Linalool,C10H18O,15%,Bioavailability Study,Nasal delivery shows 65% absorption,8.8,GRAS,Approved,PMC567890;PMC123456,Dr. Williams,Tech Lab C,Optimize formulation,£320,High,Medium,Patent application recommended
2025-01-04,TC-004,Quality Control,Alpha-Pinene,C10H16,30%,Stability Testing,Stable for 24 months under proper storage,9.0,GRAS,Approved,PMC678901;PMC234567,Dr. Brown,QC Lab D,Shelf life validation,£150,Low,High,Excellent stability profile
2025-01-05,TC-005,Therapeutic Research,Beta-Caryophyllene,C15H24,20%,CB2 Receptor Binding,Strong CB2 affinity for pain management,9.5,GRAS,Research Use,PMC789012;PMC345678,Dr. Davis,Medical Center E,Clinical trials,£450,Very High,Very High,Breakthrough therapeutic potential